GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment
E. Nuermberger, M. S. Martinez, O. Sanz, B. Urones, J. Esquivias, H. Soni, R. Tasneen, S. Tyagi, S.-Y. Li, P. J. Converse, H. I. Boshoff, G. T. Robertson, G. Besra, K. A. Abrahams, A. Upton, , E. N. Jimenez
Antimicrobial Agents and Chemotherapy · Jun 21, 2022Peer-reviewedPharmacology & Toxicology